NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association (“AHA”) Conference 2025, GENinCode ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment ...

Cardiovascular diseases (CVDs) are the leading cause of non-communicable disease (NCD) deaths in India, accounting for nearly ...

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic ...

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...

Study finds significant associations between Gulf War-related toxic chemical exposure and adverse health outcomes, including ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...

These 3 studies, to be presented at the American Heart Association (AHA) Scientific Sessions 2025, explored how these interventions can help reduce cardiovascular and cognitive risks in adults with ...

Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group ...